Presentation (CTI)

OBJECTIVES: Stakeholders may assess the value of a pharmaceutical company’s product portfolio in a specific therapeutic area during decision-making, particularly during negotiations for portfolio-based contracts or rebate programs. However, there is limited understanding of the additional types of value, beyond financial benefits, that decision-makers associate with a manufacturer providing such a portfolio. The objective of this study was to develop a survey to understand the perceptions of healthcare providers and payers in the US regarding the value (other than financial benefits) of a manufacturer providing a product portfolio.
METHODS: A non-interventional, cross-sectional survey was developed from an integrative search of academic and industry publications, as well as insights drawn from clinical practice and experience. Target respondents included those involved in purchasing, procurement, administration, or formulary management/policies of products. A portfolio was defined as a collection of ≥3 products produced by a single pharmaceutical company.
RESULTS: The resulting survey covers demographics, experience with product portfolios, themes potentially associated with portfolio value, and conclusions. The themes explored in the survey include manufacturing, procurement/inventory/storage, administration, education, transaction costs, scientific credibility, research, and therapeutic area/category considerations. Non-pharmaceutical industry analogs, such as product line length and single-supplier versus multiple-supplier procurement, were also identified as themes. The survey concludes by focusing on the impact of product portfolios on formulary decisions/policies and challenges associated with the use of a product portfolio. The survey’s structure allows a holistic assessment of stakeholder perceptions regarding product portfolio value.
CONCLUSIONS: The survey offers a structured approach to assessing the benefits stakeholders associate with a manufacturer providing a product portfolio. The survey can help quantify those benefits, allowing new themes to emerge and highlighting which hypothetical elements may not be essential. Expanding the survey to additional countries and regions would provide a broader understanding of product portfolio value in the context of different global healthcare systems.